Azulfidine
FDA Approves Simponi to Treat Ulcerative Colitis »
"The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.
Simponi works by blocking tumor necrosis factor (TNF), which plays an important"...
Read the FDA Approves Simponi to Treat Ulcerative Colitis article »
Azulfidine EN-Tabs
PATIENT INFORMATION
Patients should be informed of the possibility of adverse effects and of the need for careful medical supervision. The occurrence of sore throat, fever, pallor, purpura or jaundice may indicate a serious blood disorder. Should any of these occur, the patient should seek medical advice.
Patients should be instructed to take AZULFIDINE EN-tabs (sulfasalazine delayed release tablets) in evenly divided doses, preferably after meals, and to swallow the tablets whole. Additionally, patients should be advised that sulfasalazine may produce an orange-yellow discoloration of the urine or skin.
Ulcerative Colitis
Patients with ulcerative colitis should be made aware that ulcerative colitis rarely remits completely, and that the risk of relapse can be substantially reduced by continued administration of AZULFIDINE EN-tabs (sulfasalazine delayed release tablets) at a maintenance dosage.
Rheumatoid Arthritis
Rheumatoid arthritis rarely remits. Therefore, continued administration of AZULFIDINE EN-tabs is indicated. Patients requiring sulfasalazine should follow up with their physicians to determine the need for continued administration.
Last reviewed on RxList: 10/30/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Azulfidine EN-Tabs Information
Azulfidine EN-Tabs - User Reviews
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.






